In this webinar, featured speaker Brandon Bogdalek will interview three industry leading panelists in the diagnostics industry. The panelists will discuss best practices for bringing novel point-of-care diagnostic solutions to market. The audience will hear from founders, CEOs and executives. The panel will discuss important elements of commercialization including fundraising, prototyping, testing, engineering development and contract manufacturing.
Register today and gain insights from industry leaders on best practices for commercializing point-of-care diagnostic innovations.
(Moderator) Brandon Bogdalek, Vice President, Demand Generation, Veranex
Brandon Bogdalek is Vice President of Demand Generation at Veranex, a healthcare product innovation and commercialization partner developing solutions through human-centered design and deep engineering capability. Brandon has worked with dozens of medical device, drug delivery, diagnostics, and digital health companies on outsourced innovation and commercialization projects. In his current position, he represents the product development and engineering (PDE) function from a marketing lens – helping tell stories from internal and external subject matter experts that provide value and promote new thinking. Before Veranex, Brandon helped lead business development for several companies including Worrell Design who was purchased by Veranex in 2021. He holds a bachelor’s degree in biology from the University of Minnesota and is an active participant in several life sciences communities.
Jacob Trevino, Chief Executive Officer, Chemeleon
Jacob Trevino, PhD is currently the Chief Executive Officer at Chemeleon, a Brooklyn, NY-based start-up company developing next-generation point-of-care diagnostics for the medical community. Dr. Trevino is also an Adjunct Associate Professor at Columbia University in the Department of Electrical Engineering and founder and president of Nanotech NYC, an organization that aims to foster the continued growth of the nanotechnology community in the greater NYC area and beyond. Dr. Trevino has a BS in Physics and BA in Mathematics from Susquehanna University, a MS in Electrical Engineering from Case Western Reserve University, and a PhD in Materials Science & Engineering from Boston University. Over the years he has held the position of Nanofabrication Facility Director at the City University of New York, New York University, and the University of Pennsylvania. He also has also held senior micro-electro-mechanical systems engineering roles at Analog Devices, Inc. and Integrated Sensing Systems, Inc.
Joao Fonseca, PhD, Chief Technology Officer, Inflammatix
Joao has over 15 years of experience in developing and launching breakthrough point of care diagnostic products. Prior to joining Inflammatix, Joao was the founder and former CEO of Biosurfit where he managed multiple R&D teams in diagnostics, covering the fields of instrumentation & optical detection, microfluidics & automated sample prep, assay development and advanced computational methods to convert raw assay information into precise & accurate clinical results. Joao received a PhD in Physics from the Université Louis Pasteur of Strasbourg.
Sara Abalde-Cela, PHD, Chief Technology Officer, RUBYnanomed
Dr Sara Abalde-Cela is a co-founder and CTO of the start-up RUBYnanomed (2018 – now), having raised more than 5 million € to date. She has participated in different start-up programs internationally (Cambridge, London, Boston, Vigo, and Braga). In the course of her academic career, Sara received research awards and recognitions, as well as attracted +6 million € in competitive international and European funding as a PI, such as Pathfinder, FET Open or RIA/IA Actions. Sara holds and PhD in Physical Chemistry with specialisation in nanotechnology (Universidade de Vigo, Spain, 2013) and postdoctoral experience at the University of Cambridge (UK, 2013-2016). In 2017 she joined the International Iberian Nanotechnology Laboratory in Braga (Portugal) to develop technologies in the interface of nanosensors, microfluidics and single cancer cell studies. Despite having had some exposure to entrepreneurship both in Vigo (Spain) and Cambridge (UK), it was as a results of research and innovation developed at INL that she embarked as co-founder of the women led company RUBYnanomed, incorporated in 2018. Since then, RUBYnanomed won several national and international prizes in innovation and acceleration programmes, such as the Royal Society of Chemistry Emerging Technologies Competition in the category of Health, London, UK (2019) or the Elevator Pitch Competition (EPiC), organised by Hong Kong Science and Technology Parks Corporation in 2020. Highlighted competitive funding that Sara won as CTO of RUBYnanomed during these past years are the prestigious La Caixa Impulse Consolidate in 2020 and the EIC Accelerator in 2021. More recently, Sara was nominated as finalist (among >600 women entrepreneurs), together with the other two co-founders of RUBYnanomed, for the Women Innovators Prize of the European Innovation Council.
Who Should Attend?
- Start up or small diagnostics companies:
- Product Development
What You Will Learn
- Understand how leading diagnostics companies and leaders are thinking about their fundraising strategies
- Understand effective ways to use pre-built technology to fabricate prototypes, collect data and raise funding
- Understand important elements of commercialization, and how to best invest in technology to achieve an exit strategy
Veranex Product Design & Engineering
With a fully integrated concept-to-commercialization solution, Veranex’s design and engineering expertise sets us apart, providing you with visibility to development feasibility and opportunity along the way. Our expertise improves your launch readiness and expedites the development of your technology for regulatory and commercial success. We’re ISO 13485-certified and FDA-registered for medical technology product development, and with more than 30 years of experience and a global reach into emerging markets, our design and engineering specialization will make your MedTech vision a reality.